Can You Still Orgasm on a GLP-1?

The short version

Almost everything written about GLP-1s and sex treats libido as the whole subject. It is not. Wanting sex, becoming aroused, and being able to finish are three different functions, and they can come apart from each other. You can want it, get there physically, and still find that the ending does not arrive.

That specific question — orgasm — has almost no direct evidence in women. What exists is one case report. What surrounds it is a much better-studied proxy that points the other way, and one large exception inside that proxy which is probably the most useful thing on this page.

Scope, so you land in the right place. Whether you want sex is covered on GLP-1s and sex drive. Dryness, soreness and pain are on vaginal dryness and irritation. This page is about finishing.

The one case report, and what it actually claims

The only published account of female anorgasmia beginning after a GLP-1 was started is a 2025 case report in Sexual Medicine¹. It is worth reading carefully precisely because it is so easy to over-read.

The authors reviewed a single patient's chart and consulted a pharmacist about how these drugs might plausibly affect orgasm. They proposed two routes. The one they considered most likely is vascular: GLP-1 agonist constriction of smooth muscle reducing blood flow and oxygen delivery to the genitals, which would blunt engorgement and also impair the smooth-muscle contractions that an orgasm is physically made of. The second is central: GLP-1 receptors in the hypothalamus dampening dopamine and norepinephrine signaling, the neurotransmitters that carry motivation and pleasure.

Both of those are mechanisms the authors theorized. Neither was measured. And the whole thing rests on one woman.

What a case report is genuinely good for is putting a question on the record — it establishes that this has happened to somebody and that a plausible route exists. What it cannot tell you is how often, in whom, at which dose, or whether the drug was responsible at all. Their own conclusion asks for exactly that work: the prevalence and the mechanism both still need investigating.

If you have read a confident percentage anywhere, it did not come from here, because there is no denominator.

Why the answer is missing, which is a design problem

A 2026 review in Sexual Medicine Reviews looked at sexual dysfunction across the whole weight-loss drug class² and its findings split sharply by sex.

In men, GLP-1 receptor agonists look positive — improved erectile function, testosterone and sperm parameters. In women, the review states plainly that direct evidence remains limited. On tirzepatide specifically it notes that case reports suggest possible sexual side effects, which is the same thin evidence tier described above.

Then it names the structural reason the picture is so poor, and this is the sentence worth carrying away: across all of these drug classes, sexual endpoints were typically secondary outcomes in the trials. The answer is not being withheld. It was mostly never a primary question. The review's recommendation is that future trials measure sexual function as a primary endpoint and report results separately by sex.

So when someone tells you confidently that GLP-1s do or do not affect orgasm in women, the honest reply is that the trials were not built to find out.

The proxy evidence, and the exception that matters most

The closest well-studied analogue is major weight loss by another route. A meta-analysis of 20 studies examined female sexual function after bariatric surgery using the Female Sexual Function Index and the Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire³.

Total scores rose significantly. When the index was broken into its separate components, improvements showed up in desire, arousal, lubrication, satisfaction, pain — and orgasm. On its face that is encouraging, and it is the closest thing to good news this subject has.

Now the exception, which almost never gets quoted alongside it. In women who had pelvic floor disorders, the scores did not significantly change after surgery. Same operation, same weight loss, no measurable improvement in sexual function.

That matters more than the headline for a straightforward reason. If your pelvic floor is part of the picture — leaking, heaviness, prolapse, anything left over from birth — the general result that weight loss improves orgasm is exactly the result that was not observed in your group. It does not predict you will get worse. It says the improvement other women got was not reproduced, and that treating the pelvic floor is a separate job from losing the weight — one worth raising with a clinician on its own terms rather than filing under the medication and waiting.

The other honest caveat: this is surgery, not an injection. It is the best analogue available, not a study of these medicines.

The FAERS signal, read the right way round

One more source circulates constantly and is almost always described backwards.

A 2025 analysis in the International Journal of Impotence Research mined the FDA Adverse Event Reporting System for orgasmic dysfunction, erectile dysfunction and reduced libido linked to GLP-1 receptor agonists⁴. It found 182 reports. That number is often quoted as evidence of harm.

It is not, for two reasons.

First, it is men only. It says nothing directly about women.

Second, and more importantly, the direction is the opposite of the one usually implied. The reporting odds ratio was 0.41, with a confidence interval of 0.36 to 0.48 — entirely below 1. In this kind of analysis, below 1 means these events were reported less often for these drugs than across the database as a whole, not more. The chi-squared value was statistically significant, which is where the confusion starts, but the disproportionality measures are what carry the direction. The authors' own conclusion is that the association is weak and that overall patient risk remains low.

A database of voluntary reports cannot prove absence either, and under-reporting of sexual side effects is a known problem. But anyone citing FAERS as proof that GLP-1s damage orgasm has read the sign backwards.

How to tell what is actually happening

Not a diagnosis. A way of narrowing it before an appointment, because these lead to different conversations:

Desire is gone, and you never get as far as trying. That is the desire question, not this one — start with sex drive on a GLP-1.

You want it, arousal builds, and the ending does not come. That is anorgasmia proper, and it is the pattern the case report describes. Worth raising explicitly, in those words.

Everything is muted — sex, music, the things that usually land. Ask about mood rather than libido, especially alongside an antidepressant. See mood changes and emotional blunting.

It is friction, dryness or discomfort that stops it. That is tissue and estrogen, and unlike everything else on this page it has established treatments.

Your pelvic floor is already involved. Then the reassuring weight-loss result above is the one that did not hold for your group, and the pelvic floor is worth treating on its own terms rather than waiting for the scale.

It started exactly with the nausea and the dose climb. Tolerability effects tend to settle once the dose stops rising.

One practical note that costs nothing: name the specific function when you ask. "My libido is low" gets a shrug far more often than it should. "Desire is normal, arousal is normal, I cannot orgasm since starting this" is a clinical description, and it gets a different appointment.

Where this sits on the evidence scale

GLP-1s can cause anorgasmia in women: very low. One case report, one patient, mechanisms proposed rather than measured. Enough to take the question seriously. Not enough to attribute your experience to the drug.

Major weight loss improves orgasm: moderate. A meta-analysis of 20 studies with consistent domain-level improvements — in bariatric surgery patients, which is an analogue rather than the same intervention.

That improvement extends to women with pelvic floor disorders: contradicted. The same meta-analysis looked and found no significant change in that group.

FAERS shows a sexual-dysfunction signal for GLP-1s: no — the reverse, and in men. The reporting odds ratio sits entirely below 1.

How common any of this is in women: unknown, and structurally so. Sexual endpoints have been secondary outcomes in this whole drug class. Until a trial makes them primary and reports by sex, nobody has a rate to give you, and any page that quotes one is inventing it.